UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January 26, 2015
Kite Pharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36508 | 27-1524986 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 2225 Colorado Avenue Santa Monica, California |
90404 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (310) 824-9999
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry into a Material Definitive Agreement. |
On January 26, 2015, Kite Pharma, Inc. (“Kite”) entered into a Lease Agreement (the “Lease”) with Merritt SAB 17, LP, for the lease of approximately 18,000 square feet in Santa Monica, California. The Lease has a 10 year term commencing on February 1, 2015. Upon certain conditions, Kite has two options to extend the lease each for an additional five years. Kite is required to remit base rent of $45,540 per month, which will increase at a rate of 3% per year. Kite expects to use the newly leased space for manufacturing and processing of engineered autologous cell therapy, research and development and offices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 30, 2015 | KITE PHARMA, INC. (Registrant) | |||||
| By: | /s/ Cynthia M. Butitta | |||||
| Name: | Cynthia M. Butitta | |||||
| Title: | Chief Financial Officer and Chief Operating Officer | |||||